ERBB2 and breast cancer: In the era of precision medicine, we should select the most suitable treatment strategy by predicting the sensitivity of HER2-positive breast cancer patients to neoadjuvant therapy, aiming to achieve the best therapeutic outcomes while minimizing side effects.